Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702
Topical application allowing transdermal delivery of DYV702 at the site of the affected joint significantly reduced pain intensity and duration of acute...
Source: globenewswire.com
📰 About Dyve News
About Dyve News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from About Dyve. Real-time updates on events, politics, business and more.